Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study

Table 1 Comparing the two treatment groups for osteoarthritis

Item	Cure	Effective	Invalid	Total effective rate, %
Eucommia-meloxicam group	12	50	8	88.57
Meloxicam group	7	51	12	82.85
X2	2.126
P value	0.345

Table 2 Comparing the two treatment groups for osteonecrosis

Item	Effective	Invalid	Total effective rate, %
Eucommia-meloxicam group	67	8	89.33
Meloxicam group	55	20	73.33
X2	6.323
P value	0.012

Table 3 Comparison of the WOMAC score in the two groups of osteoarthritis patients

Item	Time	Pain	Stiff	Dysfunction
Eucommia-meloxicam group	Before treatment	13.32 ± 2.12	5.23 ± 1.14	37.23 ± 3.21
	After treatment	6.23 ± 1.23	2.38 ± 1.06	23.35 ± 2.31
	t	21.266	5.544	69.158
	P	0.000	0.000	0.000
Meloxicam group	Before treatment	14.42 ± 2.46	6.16±1.27	36.32 ± 4.17
	After treatment	3.69 ± 0.37	1.85 ± 0.26	18.37 ± 3.52
	t	30.906	60.655	45.852
	P	0.000	0.000	0.000
Comparison of the two groups before treatment	t	9.179	4.418	4.876
	P	0.000	0.000	0.000
Comparison of the two groups after treatment	t	21.551	0.74	11.508
	P	0.000	0.469	0.000

Table 4 Comparison of the Western Ontario and McMaster Universities Arthritis Index score in the two groups of osteonecrosis

Item	Time	Pain	Stiff	Dysfunction
Eucommia-meloxicam group	Before treatment	16.59 ± 2.13	6.84 ± 0.36	36.63 ± 4.21
	After treatment	7.31 ± 3.14	1.69 ± 0.23	17.42 ± 3.58
	t	27.141	53.830	52.858
	P	0.000	0.000	0.000
Meloxicam group	Before treatment	18.31 ± 3.25	7.82 ± 0.26	35.86 ± 4.36
	After treatment	5.16 ± 1.59	2.42 ± 0.19	20.16 ± 3.45
	t	25.426	57.876	29.644
	P	0.000	0.000	0.000
Comparison of the two groups before treatment	t	8.643	18.094	0.751
	P	0.000	0.000	0.453
Comparison of the two groups after treatment	t	11.006	12.114	12.379
	P	0.000	0.000	0.000

Table 5 Comparison of the two treatment groups for osteoarthritis

Item		BGP	IL-17	S100A12	SIP	Cysc	SCr	Hb
Eucommia and meloxicam group	Before treatment	2.12 ± 0.12	152 ± 6.13	43 ± 3.2	0.23 ± 0.05	0.83 ± 0.3	46 ± 4.2	132 ± 8.9
	After treatment	1.88 ± 0.35	136.44 ± 4.58	36.37 ± 5.68	0.116 ± 0.05	1.12 ± 0.5	63 ± 3.6	113 ± 12.1
	t	2.228	6.4	4.008	6.334	3.894	10.17	2.55
	P	0.053	0.000	0.003	0.000	0.004	0.000	0.031
Meloxicam group	Before treatment	0.87 ± 0.21	125 ± 6.4	32 ± 6.3	0.11 ± 0.05	0.87 ± 0.43	53 ± 4.9	124 ± 3.6
	After treatment	0.64 ± 0.19	104 ± 6.4	18 ± 3.4	0.057 ± 0.01	1.46 ± 0.42	74 ± 5.7	104.3 ± 6.8
	t	3.915	7.848	5.609	5.331	3.155	15.374	10.632
	P	0.004	0.000	0.000	0.000	0.012	0.000	0.000
Comparison of the two groups before treatment	t	30.644	12.747	5.827	6.357	3.399	7.23	2.215
	P	0.000	0.000	0.000	0.000	0.008	0.000	0.054
Comparing the two groups after treatment	t	35.845	14.523	8.409	3.174	2.774	4.97	2.456
	P	0.000	0.000	0.000	0.011	0.022	0.000	0.036

BGP: Bone-GLA protein; S100A12: Recombinant human S100 calcium binding protein A12; SIP: Sphingosine 1-phosphate; Cysc: Cystatin C; SCr: Creatinine; Hb: Hemoglobin.

Table 6 Comparison of the two treatment groups for osteonecrosis

Item		BGP	IL-17	S100A12	SIP	Cysc	SCr	Hb
Eucommia and meloxicam group	Before treatment	1.95 ± 0.17	142 ± 11.56	65 ± 4.6	0.312 ± 0.06	2.45 ± 0.21	35 ± 5.3	145 ± 6.4
	After treatment	1.64 ± 0.15	125.13 ± 13.84	42.7 ± 4.8	0.124 ± 0.04	1.42 ± 0.17	57 ± 3.5	123 ± 4.6
	t	2.419	1.432	7.924	9.185	8.175	12.513	6.713
	P	0.039	0.186	0.000	0.000	0.000	0.000	0.000
Meloxicam group	Before treatment	0.85 ± 0.13	123 ± 8.5	53 ± 4.7	0.132 ± 0.004	2.13 ± 0.11	68 ± 5.4	132 ± 5.4
	After treatment	0.58 ± 0.21	98.1 ± 12.9	16.38 ± 3.5	0.069 ± 0.005	1.69 ± 0.19	82 ± 3.5	105 ± 4.7
	t	3.723	3.517	14.093	5.506	4.856	5.239	13.069
	P	0.005	0.007	0.000	0.000	0.001	0.001	0.000
Comparison of the two groups before treatment	t	15.74	7.292	3.17	8.95	4.848	10.548	5.745
	P	0.000	0.000	0.011	0.000	0.001	0.000	0.000
Comparison of the two groups after treatment	t	11.959	10.409	9.833	4.25	4.013	12.444	9.21
	P	0.000	0.000	0.000	0.002	0.003	0.000	0.000

BGP: Bone-GLA protein; S100A12: Recombinant human S100 calcium binding protein A12; SIP: Sphingosine 1-phosphate; Cysc: Cystatin C; SCr: Creatinine; Hb: Hemoglobin.